|
A double blind, randomized, placebo-controlled,
parallel group trial was conducted in patients of either sex, age ranging from
22 to 53 years, having undergone bone lengthening operation. CalSorb appears to
exert beneficial effects on the course of bone healing. The quality of callus
and maturation of bone was found to be good in 40% and excellent in 60% patients
receiving CalSorb. None of the patients receiving CalSorb required any external
process like dynamisation for bone maturation. At the end of the study, 90% patients
in CalSorb group regained their ability to perform the daily routine. None of
the patients receiving CalSorb experienced any adverse effects. CalSorb did not
alter the organ functions and also did not affect the electrolyte levels of calcium,
Magnesium or Phosphorus. Thus CalSorb appears to be effective and safe to facilitate
healing of bones. Dahanukar
S.A. et. al.(2005), The Antispetic 102 (10) : 582-585. Use
of CalSorb during last trimester of pregnancy not only helped in meeting higher
demands of Ca, P, and Mg, also there was increased osteoblastic activity (new
bone deposition) while in control group there was a tendency for osteoclastic
activity (mobilization of bone reserves), as shown by enzyme activity and analysis
of bone biopsy material. Higher levels of serum Ca, P and Mg were observed particularly
for ionised Calcium, which were statistically significant. Therefore, CalSorb
can be used successfully for prophylaxis of calcium deficiency syndromes and can
also prepare the individuals to better respond to the increased demands on Ca,
P and Mg that pregnancy or lactation imposes. Dr.
Philipov J.P. et. al., Bulgaria. (1994) Indian J. Indg. Med. 16(2): 67-72.
At
fracture site in long bones, CalSorb activated the proliferation of fine capillaries
ensuring early elimination of necrotic material and tissue debris. Angiography
showed better vascular pattern alongwith proliferation of osteogenic cells and
formation of organic matrix followed by early union of medullary vessels of both
the fractured fragments. Radiographic examination revealed a well organized and
dense callus obliterating the fracture line completely at 6th week as compared
to the same in control group at the 9th week.
Singh,
Harnam, Singh, Harpal. Indian J. Indg. Med. 17(2), Oct, 1995-March 1996.
CalSorb
was found to be safe and free from teratogenic and embryotoxic effects when given
upto 10 times higher than recommended dose. The Crown Rump Length and Umbilical
Cord Length of foetuses and Plancental weight were significantly higher in CalSorb
treated groups. This facilitated optimum supply of nutrients to growing foetuses
as they were comparatively better in size, musculature and skeletal development
alongwith higher body weight. There was no defect in ossification of cranial vault
and long bones in CalSorb treated groups. The dry weight of foetuses was also
comparatively higher in CalSorb treated groups. The calcium and phosphorus homeostasis
was maintained in pregnant rats of CalSorb group. CalSorb did not show any maternal
toxic effect with respect to food and water intake or gain in body weight.
Dr.
Das, S. N., Chatterjee S, Agrawala, S.K.; Paper presented at XXX Annual IPS conference
(1997), Jammu.
CalSorb
exhibited non-toxic nature and high safety profile during long term toxicity studies
with doses upto 10 times higher than recommended dose. There was no change or
adverse effect on blood biochemical profile, haematological values and liver &
kidney function. There was no mineralisation of soft tissue or any sign of hypercalcaemia
or hyperphosphataemia. Unlike Vitamin-D toxicity, there was no ectopic calcification
of urinary tract. There was no calcification of endocardium and walls of large
blood vessels confirming that there was no untoward effect on heart due to prolonged
administration of CalSorb.
Dr.
Chatterjee, S., Das, S.N.; Accepted for publication in Indian J. Indg. Med. | 